167 results
Page 4 of 9
8-K
EX-99.1
ygd3vkn
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
7egpx 67u5ptcgko6z9
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
8-K
EX-10.1
zwnf4nixsjqy0ixece
21 May 21
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
xfoy5o8o 83
21 May 21
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
7:28am
8-K
EX-99.1
f24k226210s
18 May 21
Other Events
3:09pm
8-K
EX-99.1
d6m4gvph o6w
11 May 21
Other Events
8:34am
8-K
EX-99.2
gbemil9 l2h
11 May 21
Other Events
8:34am
8-K
EX-99.1
hmjw bkz0obg
10 May 21
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
4:15pm
8-K
EX-99.1
slpczu4w8
4 Mar 21
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
7:30am
8-K
EX-99.2
8fmsl4uhyce sr01z
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.1
ucbn md141ol7ot9zu
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.2
sojk5j
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm
8-K
EX-99.1
em8vfm2 25v4x0jg2p4
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm
8-K
EX-10.1
mpui1ryj
30 Oct 20
Entry into a Material Definitive Agreement
5:02pm